Targeted delivery of nitric oxide via a ‘bump-and-hole’-based enzyme–prodrug pair

The spatiotemporal generation of nitric oxide (NO), a versatile endogenous messenger, is precisely controlled. Despite its therapeutic potential for a wide range of diseases, NO-based therapies are limited clinically due to a lack of effective strategies for precisely delivering NO to a specific site. In the present study, we developed a novel NO delivery system via modification of an enzyme–prodrug pair of galactosidase–galactosyl-NONOate using a ‘bump-and-hole’ strategy. Precise delivery to targeted tissues was clearly demonstrated by an in vivo near-infrared imaging assay. The therapeutic potential was evaluated in both rat hindlimb ischemia and mouse acute kidney injury models. Targeted delivery of NO clearly enhanced its therapeutic efficacy in tissue repair and function recovery and abolished side effects due to the systemic release of NO. The developed protocol holds broad applicability in the targeted delivery of important gaseous signaling molecules and offers a potent tool for the investigation of relevant molecular mechanisms.A NO delivery system that depends on the hydrolysis of an alkyl-galactose-conjugated NO prodrug by an engineered galactosidase developed using a ‘bump-and-hole’ strategy enabled targeted delivery of NO to specific tissues.

[1]  Christian Bogdan,et al.  Nitric oxide and the immune response , 2001, Nature Immunology.

[2]  L. Shinobu,et al.  Sodium N-methyl-D-glucamine dithiocarbamate and cadmium intoxication. , 2009, Acta pharmacologica et toxicologica.

[3]  R. Kalluri,et al.  Origin and function of myofibroblasts in kidney fibrosis , 2013, Nature Medicine.

[4]  Jarkko Rautio,et al.  Prodrugs in medicinal chemistry and enzyme prodrug therapies , 2017, Advanced drug delivery reviews.

[5]  E. Place,et al.  Complexity in biomaterials for tissue engineering. , 2009, Nature materials.

[6]  L. Lazzarato,et al.  A Nitric Oxide-Donor Furoxan Moiety Improves the Efficacy of Edaravone against Early Renal Dysfunction and Injury Evoked by Ischemia/Reperfusion , 2015, Oxidative medicine and cellular longevity.

[7]  S Amerini,et al.  Nitric oxide mediates angiogenesis in vivo and endothelial cell growth and migration in vitro promoted by substance P. , 1994, The Journal of clinical investigation.

[8]  Nick D. Tsihlis,et al.  Nitric oxide and nanotechnology: a novel approach to inhibit neointimal hyperplasia. , 2008, Journal of vascular surgery.

[9]  Benjamin G Davis,et al.  The crystal structure of two macrolide glycosyltransferases provides a blueprint for host cell antibiotic immunity , 2007, Proceedings of the National Academy of Sciences.

[10]  Youhua Liu,et al.  Renal fibrosis: new insights into the pathogenesis and therapeutics. , 2006, Kidney international.

[11]  C. Tallant,et al.  New Synthetic Routes to Triazolo-benzodiazepine Analogues: Expanding the Scope of the Bump-and-Hole Approach for Selective Bromo and Extra-Terminal (BET) Bromodomain Inhibition , 2015, Journal of medicinal chemistry.

[12]  R. Farrar,et al.  Therapeutic assessment of mesenchymal stem cells delivered within a PEGylated fibrin gel following an ischemic injury. , 2016, Biomaterials.

[13]  L. Keefer,et al.  Chemistry of the nitric oxide-releasing diazeniumdiolate ("nitrosohydroxylamine") functional group and its oxygen-substituted derivatives. , 2002, Chemical reviews.

[14]  C. Springer,et al.  Antibody-directed enzyme prodrug therapy (ADEPT): a review. , 1997, Advanced drug delivery reviews.

[15]  K. Torii,et al.  Chemical hijacking of auxin signaling with an engineered auxin-TIR1 pair , 2017, Nature chemical biology.

[16]  M. J. Olesen,et al.  Enzyme Prodrug Therapy Engineered into Electrospun Fibers with Embedded Liposomes for Controlled, Localized Synthesis of Therapeutics , 2017, Advanced healthcare materials.

[17]  W. Abraham,et al.  Macrocyclic trichothecenes as antifungal and anticancer compounds. , 2015, Current Medicinal Chemistry.

[18]  J. D. Berg,et al.  Rapid detection of total and fecal coliforms in water by enzymatic hydrolysis of 4-methylumbelliferone-beta-D-galactoside , 1988, Applied and environmental microbiology.

[19]  M. Burnett,et al.  Local Delivery of Marrow-Derived Stromal Cells Augments Collateral Perfusion Through Paracrine Mechanisms , 2004, Circulation.

[20]  J. Cooke.  NO and angiogenesis. , 2003, Atherosclerosis. Supplements.

[21]  Qiang Zhao,et al.  Polysaccharide-based biomaterials with on-demand nitric oxide releasing property regulated by enzyme catalysis. , 2013, Biomaterials.

[22]  Paul L Huang,et al.  Cardiovascular roles of nitric oxide: a review of insights from nitric oxide synthase gene disrupted mice. , 2007, Cardiovascular research.

[23]  Rakesh K Jain,et al.  Molecular regulation of vessel maturation , 2003, Nature Medicine.

[24]  A. Zelikin,et al.  Enzyme prodrug therapies and therapeutic enzymes. , 2017, Advanced drug delivery reviews.

[25]  R. Sorelle.  Nobel prize awarded to scientists for nitric oxide discoveries. , 1998, Circulation.

[26]  J. Min,et al.  Defining efficient enzyme–cofactor pairs for bioorthogonal profiling of protein methylation , 2013, Proceedings of the National Academy of Sciences.

[27]  R. E. Huber,et al.  Trp-999 of beta-galactosidase (Escherichia coli) is a key residue for binding, catalysis, and synthesis of allolactose, the natural lac operon inducer. , 2003, Biochemistry.

[28]  Qiang Zhao,et al.  Enhanced proangiogenic potential of mesenchymal stem cell-derived exosomes stimulated by a nitric oxide releasing polymer. , 2017, Biomaterials.

[29]  N. Vaziri.  HDL abnormalities in nephrotic syndrome and chronic kidney disease , 2016, Nature Reviews Nephrology.

[30]  U. Förstermann,et al.  Nitric oxide synthases: regulation and function. , 2012, European heart journal.

[31]  A. Ahluwalia,et al.  Antiinflammatory actions of inorganic nitrate stabilize the atherosclerotic plaque , 2017, Proceedings of the National Academy of Sciences.

[32]  P. D. De Jager,et al.  Blood kidney injury molecule-1 is a biomarker of acute and chronic kidney injury and predicts progression to ESRD in type I diabetes. , 2014, Journal of the American Society of Nephrology : JASN.

[33]  P. Wang,et al.  Synthesis and enzyme-specific activation of carbohydrate-geldanamycin conjugates with potent anticancer activity. , 2005, Journal of medicinal chemistry.

[34]  Philippe Leboulch,et al.  Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2 , 2003, Nature Medicine.

[35]  Peter Carmeliet,et al.  Angiogenesis in life, disease and medicine , 2005, Nature.

[36]  M. R. Miller,et al.  Recent developments in nitric oxide donor drugs , 2007, British journal of pharmacology.

[37]  Molly M. Stevens,et al.  Localized and Controlled Delivery of Nitric Oxide to the Conventional Outflow Pathway via Enzyme Biocatalysis: Toward Therapy for Glaucoma , 2017, Advanced materials.

[38]  Qiang Zhao,et al.  IGF-1 C Domain-Modified Hydrogel Enhances Cell Therapy for AKI. , 2016, Journal of the American Society of Nephrology : JASN.

[39]  N. Fineberg,et al.  Augmentation of Intrapericardial Nitric Oxide Level by a Prolonged-Release Nitric Oxide Donor Reduces Luminal Narrowing After Porcine Coronary Angioplasty , 2002, Circulation.

[40]  Qingbo Xu,et al.  Enzyme-functionalized vascular grafts catalyze in-situ release of nitric oxide from exogenous NO prodrug. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[41]  J. Edwards,et al.  Exploring the full spectrum of macrophage activation , 2008, Nature Reviews Immunology.

[42]  K. Shokat,et al.  Engineering unnatural nucleotide specificity for Rous sarcoma virus tyrosine kinase to uniquely label its direct substrates. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[43]  M. Gladwin,et al.  Strategies to increase nitric oxide signalling in cardiovascular disease , 2015, Nature Reviews Drug Discovery.

[44]  T. Nagano,et al.  Bioimaging of nitric oxide. , 2002, Chemical reviews.

[45]  P. Carmeliet,et al.  Drug discovery: A lifeline for suffocating tissues , 2008, Nature.

[46]  P. Wang,et al.  Sialated diazeniumdiolate: a new sialidase-activated nitric oxide donor. , 2004, Organic letters.

[47]  Y. B. Sun,et al.  The origin of renal fibroblasts/myofibroblasts and the signals that trigger fibrosis. , 2016, Differentiation; research in biological diversity.

[48]  Peter G. Schultz,et al.  A chemical switch for inhibitor-sensitive alleles of any protein kinase , 2000, Nature.

[49]  K. Connelly,et al.  eNOS deficiency predisposes podocytes to injury in diabetes. , 2012, Journal of the American Society of Nephrology : JASN.

[50]  Mark T. Gladwin,et al.  The nitrate–nitrite–nitric oxide pathway in physiology and therapeutics , 2008, Nature Reviews Drug Discovery.

[51]  Kwok-Ho Chan,et al.  A bump-and-hole approach to engineer controlled selectivity of BET bromodomain chemical probes , 2014, Science.

[52]  B. Ramakrishnan,et al.  Structure-based design of beta 1,4-galactosyltransferase I (beta 4Gal-T1) with equally efficient N-acetylgalactosaminyltransferase activity: point mutation broadens beta 4Gal-T1 donor specificity. , 2002, The Journal of biological chemistry.

[53]  R. Jain,et al.  NO mediates mural cell recruitment and vessel morphogenesis in murine melanomas and tissue-engineered blood vessels. , 2005, The Journal of clinical investigation.

[54]  J. Megyesi,et al.  Metabolomic study of cisplatin-induced nephrotoxicity. , 2006, Kidney international.

[55]  P. Wang,et al.  Glycosylated diazeniumdiolates: a novel class of enzyme-activated nitric oxide donors , 2001 .